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Species B adenovirus serotypes 3, 7, 11 and 35 share similar
binding sites on the membrane cofactor protein CD46 receptor
Abstract
We recently characterized the domains of the human cofactor protein CD46 involved in binding species
B2 adenovirus (Ad) serotype 35. Here, the CD46 binding determinants are mapped for the species B1
Ad serotypes 3 and 7 and for the species B2 Ad11. Ad3, 7 and 11 bound and transduced CD46-positive
rodent BHK cells at levels similar to Ad35. By using antibody-blocking experiments, hybrid CD46-CD4
receptor constructs and CD46 single point mutants, it is shown that Ad3, 7 and 11 share many of the
Ad35-binding features on CD46. Both CD46 short consensus repeat domains SCR I and SCR II were
necessary and sufficient for optimal binding and transgene expression, provided that they were
positioned at an appropriate distance from the cell membrane. Similar to Ad35, most of the putative
binding residues of Ad3, 7 and 11 were located on the same glycan-free, solvent-exposed face of the
SCR I or SCR II domains, largely overlapping with the binding surface of the recently solved fiber knob
Ad11-SCR I-II three-dimensional structure. Differences between species B1 and B2 Ads were
documented with competition experiments based on anti-CD46 antibodies directed against epitopes
flanking the putative Ad-binding sites, and with competition experiments based on soluble CD46
protein. It is concluded that the B1 and B2 species of Ad engage CD46 through similar binding surfaces.
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2SUMMARY22
We recently characterised the domains of the human cofactor protein CD46 involved23
in binding of species B2 adenovirus serotype 35.  Here we map the CD46 binding24
determinants for the species B1 Ad serotypes 3 and 7, and for the species B2 Ad11.25
Ad3, 7 and 11 bound and transduced CD46-positive rodent BHK cells at similar26
levels as Ad35 did.  Using antibody-blocking experiments, hybrid CD46-CD4 receptor27
constructs and CD46 single point mutants, we show that Ad3, 7, and 11 share many28
of the Ad35 binding features on CD46.  Both CD46 short consensus repeat domains29
SCR I and SCR II were necessary and sufficient for optimal binding and transgene30
expression, provided that they were positioned at an appropriate distance from the31
cell membrane.  Similar to Ad35, most of the putative binding residues of Ad3, Ad732
and Ad11 were located on the same, glycan-free solvent-exposed face of the SCR I33
or SCR II domains, largely overlapping with the binding surface of the recently solved34
fibre knob Ad11-SCR I-II 3D structure.  Differences between species B1 and B2 Ads35
were documented with competition experiments based on anti-CD46 antibodies36
directed against epitopes flanking the putative Ad binding sites, and with competition37
experiments based on soluble CD46 protein.  We conclude that two B1 and B238
species Ads engage CD46 through similar binding surfaces.39
40
41
INTRODUCTION42
The 51 serotypes of human Adenoviridae are classified into six species, A to F43
(Benkö et al., 2000, Horwitz, 2001), and species B adenoviruses (Ads) are further44
divided into B1 and B2 serotypes, for which tropism differs.  The B1 group comprises45
Ad3, Ad7, Ad16, Ad21 and Ad50 and predominantly infects the upper respiratory46
tract, whereas the B2 group serotypes Ad11, Ad14, Ad34 and Ad35 are associated47
with kidney and urinary tract infections with fatal outcome in immunocompromised48
patients (Leen & Rooney, 2005, Schmitz et al., 1983, Wadell, 2000).49
3Species B Ads bind a different cell surface receptor than most of the species A, C, D,50
E, and F Ad serotypes, which bind to the Coxsackievirus and Adenovirus Receptor51
(CAR) (Bergelson et al., 1997, Defer et al., 1990, Roelvink et al., 1998, Stevenson et52
al., 1995).  Several groups have identified the membrane cofactor CD46 as an53
attachment receptor for species B serotypes, including Ad11 (Segerman et al.,54
2003b), Ad35 (Gaggar et al., 2003) and Ad3 (Sirena et al., 2004).  CD46 belongs to a55
family of regulators of complement activation, whose biological role is to prevent56
complement activation on autologous tissue (Liszewski et al., 1991).  Based on virus57
competition experiments and antibody-mediated blocking of various Ads on human58
cells, it has been suggested that more than one species B receptor exists (Segerman59
et al., 2003a, Sirena et al., 2004, Tuve et al., 2006), and it remains controversial60
whether CD46 functions as attachment receptor for all species B serotypes (Gaggar61
et al., 2003, Gustafsson et al., 2006, Marttila et al., 2005, Segerman et al., 2003b,62
Tuve et al., 2006).  Additional Ads that bind to CD46 include species D Ad37 and63
Ad49 (Lemckert et al., 2006, Wu et al., 2004).64
CD46 consists of (i) four amino-terminal copies of an approximately 60-amino-acid65
structural motif, termed short consensus repeat SCR, (ii) 1-3 serine/threonine/proline-66
rich (STP) domains, (iii) a short region of unknown function, (iv) a transmembrane67
spanning domain, and (v) a carboxy-terminal cytoplasmic tail.  Alternative splicing of68
the STP domain-encoding exons (STABC) and cytoplasmic tail exons (CYT1 and69
CYT2) gives rise to four major splice variants C1, C2, BC1 and BC2 and to additional70
minor variants (Liszewski et al., 1991).  Domains SCR I, SCR II and SCR IV each71
contain one N -linked oligosaccharide.  The binding regions of the various72
physiological and microbial ligands involve all domains of CD46 (Cattaneo, 2004).73
Measles virus interacts with SCR I-II, whereas SCR III and SCR IV have an74
accessory role for optimal binding and receptor down-regulation (Buchholz et al.,75
1997, Devaux et al., 1997, Manchester et al., 1997).  Binding of human Ad35 to76
CD46 occurs through SCR I-II (Fleischli et al., 2005, Gaggar et al., 2005, Sakurai et77
al., 2006), with most putative binding residues located on the same solvent-exposed78
face of the SCR I or SCR II domains.79
4In this study we asked whether other species B serotypes including Ad3 and Ad780
from species B1, and Ad11 from species B2 engage CD46 through similar binding81
surfaces.  We used a similar approach as for the characterization of Ad35 binding.82
We measured binding and transgene expression with chimeric CD46 SCR-CD483
receptor proteins, and different CD46 single amino acid mutants in the SCR I-II84
domains, as well as virus binding efficiencies in competition with anti-CD4685
antibodies and a soluble, extracellular CD46 domain.  The crystal structure of the86
species B Ad11 knob complexed with CD46 SCR I-II was published.  It revealed87
three contact areas along the entire length of the glycan-free side of the receptor88
(Persson et al., 2007).  We show here that the binding sites of Ad3, Ad7 and Ad1189
overlap largely with the earlier predicted binding site for Ad35.  Moreover, these sites90
are in the binding surface of the resolved fibre knob Ad11-SCR I-II 3D structure.91
92
93
METHODS94
Cells, viruses and eGFP expression analyses.  The human A549 lung carcinoma95
and 911 embryonic kidney cells, the mouse fibroblast cell line Ltk-, and the baby96
hamster kidney cell line BHK-21 expressing the BC1 splice isoform of CD46 and CAR97
were described previously (Sirena et al., 2004).98
Ad3 (prototype strain GB), Ad7 (prototype strain Gomen) and Ad11p were radio99
labelled as described earlier (Fleischli et al., 2005).  Specific activities were in the100
range of 2.6 x 10-5 to 4.9 x 10-5 cpm/virus particle (vp).  Construction of recombinant,101
E1 / E3-deleted Ad11 vector expressing eGFP and luciferase have been described102
previously (Holterman et al., 2004).  Ad3CMV-eGFP and Ad7CMV-eGFP containing103
the CMV-eGFP or CMV-luciferase expression cassette in the deleted E1 region were104
constructed using a recently developed recombineering protocol (Warming et al.,105
2005) (http://recombineering.ncifcrf.gov/) (supplementary data).  Virus particle106
concentration of the eGFP-expressing viruses was determined by adsorbance at 600107
nm of the hexon protein by the use of a highly purified wtAd5 as standard.  Virion108
concentration of wtAd5 itself was determined according to Maizel et al. (Maizel et al.,109
51968), and found to be 1.3x1012 vp/ml.  Concentrations determined were 7.1x1011110
vp/ml for Ad3CMV-eGFP, 1.6x1011 vp/ml for Ad7CMV-eGFP and 6.6x1011 vp/ml for111
Ad11CMV-eGFP.112
113
Antibodies and flow cytometric analysis.  Cytofluorometric analysis, CD46- and114
CAR-specific antibodies and secondary fluorochrome conjugates have been115
described previously (Ebbinghaus et al., 2001, Fleischli et al., 2005).  For eGFP116
expression analysis, triplicates of 1 x 105 cells were infected at MOIs of 1, 10, 100, or117
1000 vp.  Medium was replaced 3 h p.i. and cells were analyzed two days p.i. by flow118
cytometric analysis.119
120
Virus binding and blocking.  Binding and blocking experiments were performed as121
described previously (Fleischli et al., 2005, Nagel et al., 2003).122
123
Binding and transgene expression using hybrid CD46-CD4 and single point124
mutant proteins.  Generation and composition of hybrid CD46-CD4 constructs,125
single point mutants and the six-amino acid exchange mutant P39-T44 were126
described previously (Fleischli et al., 2005).  Transient expression of the hybrid127
CD46-CD4 and single point mutant proteins were accomplished in two cell types,128
either mouse Ltk- cells (for binding analysis) or hamster BHK cells (for transgene129
expression).  Cells were grown to 70-90% confluency and were transiently130
transfected using the vaccinia virus T7 expression system (Fuerst et al., 1986).  Cells131
were infected with vaccina virus VTF7-3 at a MOI 10 - 15 for 40 min.  The virus was132
removed and cells were transfected with plasmid DNA encoding the different CD46133
constructs using the protocol of the manufacturer (Polyplus-transfection SA).  The134
cells were harvested about 20 h after transfection by detaching from the dish by PBS-135
EDTA treatment.  After washing twice with DMEM-8% FBS, the cells were aliquoted136
for cytometric analysis (see above), binding assay or transgene expression137
experiments.  For binding assays 3.5 – 5 x 105  cells were incubated with radio138
labelled virus.  For transgene expression 5 x 105 cells / well were seeded in 12-well139
6plates and allowed to attach for at least 5 h, followed by addition of 750 vp/cell of140
Ad3CMV-Luc and Ad11CMV-Luc.  Twenty-four hours p.i. cells were harvested, and141
luciferase activity was determined as described above.  The luciferase activities were142
normalized to the lysate protein concentration.  Binding efficiencies and transgene143
expression levels were obtained by dividing binding values (cpm bound [3H]-Ad144
minus cpm cells alone) or transgene expression levels (RLU infected cells minus145
RLU cells alone) by the levels of hybrid surface expression.  All measurements146
including surface expression analysis were done in triplicates and repeated at least147
three times.  Individual CD46 expression levels were similar in BHK cells compared148
to Ltk- cells, however background luciferase levels were much lower in BHK cells.149
150
151
RESULTS152
153
All four B serotype viruses Ad3, Ad7, Ad11 and Ad35 use CD46 as attachment154
receptor.155
We first confirmed and extended observations that CD46 serves as a receptor for156
different species B Ads.  A549 lung carcinoma cells, rodent BHK cells or BHK cells157
stably expressing the BC1 CD46 isoform (BHK-CD46), or CAR (BHK-CAR) (Sirena et158
al., 2004) were used for binding or transgene expression assays.  For comparative159
binding assays, cells were incubated with 1000 particles per cell of [3H]-thymidine-160
labelled wild type Ad3, Ad7, Ad11, Ad35, or the species C Ad5 and the number of161
cell-associated particles was determined (Fig. 1A).  A549, which expressed high162
levels of CD46 (mean fluorescence intensity (MFI) of 61.8) revealed 4 - 11% binding163
of the input viruses, with two to threefold more Ad35 and Ad11 bound particles than164
Ad3 and Ad7.  BHK-CD46 cells expressing about two-fold more CD46 (MFI of 113)165
revealed a slightly higher Ad11 binding (increase of 22%) and a weakly reduced Ad3,166
Ad7 and Ad35 binding (decrease of 36, 27 and 8%, respectively) as compared to167
A549 cells.  This could be due to additional, alternative receptor usage of some168
species B serotypes in human A549 cells (see discussion).  In contrast, parental BHK169
7and BHK-CAR cells bound 6 to 17-times less labelled species B viruses, when170
compared to the BHK-CD46 cells. Similarly, high levels of Ad5 binding were found in171
A549 and BHK-CAR cells, but not in parental BHK and BHK-CD46 cells.  When172
eGFP transgene expression was analyzed following inoculation with increasing173
amounts of recombinant Ad3, Ad7, Ad11 and Ad35 expressing eGFP, a robust 1-2-174
log increase was documented in BHK-CD46 compared to the parental BHK or BHK-175
CAR cells (Fig. 1B).  Of note, although binding of serotype B Ads was similar in the176
BHK-CD46 cells compared to A549 cells, transgene expression was about 30 to 50-177
fold lower than in A549 cells.  A similar effect was found when BHK-CAR cells and178
Ad5-based eGFP vector was utilized.  Thus, the findings that CD46 serves as a179
receptor for Ad3, Ad7, Ad11 and Ad35 species B Ads are in full agreement with our180
earlier identification of CD46 as an Ad receptor with chimeric Ad5 vectors harbouring181
the fibres of Ad7, 11, 16, 35 or 50 (Fleischli et al., 2005), or Ad3-based eGFP vectors182
(Sirena et al., 2004, Sirena et al., 2005).183
184
Antibody- and soluble CD46-mediated blocking of species B Ads binding to185
CD46.186
To check whether Ad3, Ad7 and Ad11 bind the same distal CD46 SCR domains I and187
II involved in Ad35 binding (Fleischli et al., 2005, Gaggar et al., 2005, Sakurai et al.,188
2006), seven monoclonal antibodies with specificity for individual SCR domains were189
tested for their efficacy to inhibit binding of [3H]-Ads to CD46, as reported previously190
for Ad3 (Sirena et al., 2004) and Ad35 (Fleischli et al., 2005).  Hereto, BHK-CD46191
cells were first incubated with monoclonal antibodies at various concentrations,192
followed by addition of [3H]-thymidine-labelled Ads, and determination of cell-193
associated virus (Fig. 2A, summarized for all four viruses in Fig. 2B).194
The two SCR I-specific monoclonal antibodies 13/42 and MEM-258, as well as the195
SCR II-specific M177 strongly inhibited binding of all four serotypes in a196
concentration-dependent manner.  The SCR III/IV-specific antibody GB-24 inhibited197
Ad3 and Ad7 binding more efficiently to about 70 to 80% at the highest198
concentrations used, compared to about 30% of Ad11 (and Ad35 (Fleischli et al.,199
82005)).  Finally the three SCR I-specific antibodies E4.3, MCI20.6 and Tra-2 had in200
general weaker, but variable effects on binding of the various serotypes.  E4.3201
revealed an intermediate 52% inhibition on Ad3 and Ad7 binding, but essentially no202
effect on Ad11 and Ad35 binding.  The MCI20.6 antibody had no effect on Ad3 and203
Ad7 binding and a significant but weak effect on Ad11 and Ad35 binding.  Finally, the204
Tra-2 antibody had a stronger effect on Ad3 and Ad7 with 35% inhibition than on205
Ad11 and Ad35 binding, with 12 and 21% binding inhibition.  Together, these data206
suggest that similar to Ad35, mainly SCRs I and II are involved in Ad3, Ad7 and Ad11207
binding, but that subtle differences in the binding sites may exist.208
To further characterize the binding affinities of the three different Ads, we studied the209
blocking capacity of soluble CD46ex-Fc (Sirena et al., 2004), which forms a dimeric210
protein containing two CD46 binding sites similar to CARex-Fc that leads to Ad5211
aggregate formation through multivalency ((Ebbinghaus et al., 2001, Meier et al.,212
2005) and unpublished data).  We found that the soluble CD46ex-Fc protein, which213
contained the complete extracellular receptor domain, inhibited binding of all three214
Ads to BHK-CD46 in a dose-dependent manner (Fig. 2C), whereas the control215
CARex-Fc protein had no significant effect on species B binding (only shown for216
Ad3).  However, CD46ex-Fc protein was about 100-fold more potent in blocking Ad11217
(and Ad35 (Fleischli et al., 2005)) binding compared to Ad3 or Ad7 binding (Fig 2C).218
219
Mapping Ad3, Ad7, Ad11 binding domains with hybrid CD46-CD4 proteins.220
We next mapped the amino acids of CD46 involved in binding of Ad3, Ad7 and Ad11221
using a set of ten CD46 hybrid receptors.  The hybrid receptors consisted of different222
CD46 SCR domains fused to CD4 Ig-like modules (Buchholz et al., 1996,223
Mumenthaler et al., 1997).  Using a first set of four constructs we tested binding and224
transduction efficiencies mediated by the four SCR domains fused to increasing225
numbers of CD4 Ig-like domains (Fig. 3A, C, E).  Binding and luciferase transgene226
expression were normalized to the cell surface expression levels of the construct227
which could vary by up to 3-fold.  The CD4 domains function as spacers increasing228
the distance between the potential CD46 binding site of Ad and the plasma229
9membrane.  Single SCR domains have a size similar to Ig domains and each Ig230
domain is expected to increase the distance to the membrane by about 30 Å (Bork et231
al., 1996).  Overall, no drastic differences were found for the four constructs when232
binding of the three viruses was analyzed.  A small reduction of Ad3 and Ad11233
binding was noticed for the shortest I-IV construct, as well as for Ad7 and the I-IV/4234
construct.  Construct I-IV/3-4 was slightly more efficient at Ad3 and Ad11 binding.235
Ad3 and Ad11-mediated transgene expression increased with the receptor length236
(Ad7 was not included in these analyses).  Increasing the receptor length by one, two237
or four Ig modules increased the Ad3 transgene expression to 150 to 250% of wt238
CD46, and the latter two constructs also resulted in similarly enhanced Ad11-239
mediated reporter expression (Fig 3C, E).240
The second set of CD4-CD46-SCR hybrid constructs contained the two outer SCR241
domains SCR I-II, either alone (I-II), or fused to increasing numbers of CD4 Ig242
domains (I-II/4, I-II/3-4, I-II/1-4).  Two additional constructs including the I-II/4 type243
construct also contained the single point mutations N49Q (I-II/4 dg1) and N80Q (I-II/4244
dg2) ablating the N-glycosylation site of these domains.  We found that an extension245
of the CD46 SCR I-II construct by two (construct I-II/3-4) or four CD4 domains246
(construct I-II/1-4) resulted in virus binding similar to that of CD46-expressing cells for247
all three viruses (Fig. 3B, D, F).  This was paralleled by increased transgene248
expression, reaching maximally about 150% (construct I-II/3-4 and Ad3) or 170%249
(construct I-II/1-4 and Ad11) over CD46 alone.  The shorter constructs I-II and I-II/4250
yielded about 25% to 50% of wt CD46 binding with all three viruses, and a low251
reduction of transgene expression.  Ablation of neither the SCR I nor the SCR II N-252
linked glycosylation did significantly affect virus binding or transgene expression253
when compared to construct I-II/4.  As for Ad35, the data suggest that SCR I and II254
are sufficient for Ad3, Ad7 and Ad11 binding and transgene expression, and that the255
distance of these domains from the plasma membrane influences transgene256
expression efficiency.257
258
Mapping Ad3, Ad7, and Ad11 binding residues with 36 single amino acid SCR-I-259
II mutant proteins.260
10
To define residues involved in Ad3, Ad7, and Ad11 binding, a set of 36 CD46261
mutants containing semi-conservative changes of single amino acids within the262
SCR I-II domains were tested (Buchholz et al., 1997).  These mutations involved263
residues predicted to be on the CD46 SCR I-II solvent exposed surface264
(Mumenthaler et al., 1997), and consisted of replacements by small residues (alanine265
for charged and polar, serine for apolar residues).  Use of such semi-conservative266
changes is expected to be well tolerated and to have minimal impact on protein267
conformation.  Also included was a six amino acid exchange mutant 39PLATHT44268
containing six alanines replacing the endogenous sequence.  Analysis of Ad3, Ad7269
and Ad11 binding was performed as for the hybrid constructs and binding data are270
summarized in Fig. 4.  Not all of the alterations described to decrease Ad35 binding271
(Fleischli et al., 2005) resulted in similar binding reduction of Ad3, Ad7 and Ad11.272
Among the 19 mutant CD46 proteins with alterations in the SCR I domain, a weak but273
consistent binding reduction for all four Ad serotypes was documented for the K29A274
mutations with about 20% decrease in binding.  Both closely and more distantly275
located residues influenced binding of some, but not all Ads.  For instance mutations276
in the K15, E24 and R25 residues reduced binding of Ad11 and Ad35, but not of Ad3277
and Ad7.  Mutation of residue K31 affected Ad7, and 11 but not Ad3 and 35.278
Similarly, alterations of P39, P39-T44, and L40 affected variably three of the four279
viruses.  These residues are situated on the same face of the SCR I solvent-exposed280
surface as the epitopes characterized by antibodies 13/42, some of them contiguous281
(Fig. 5A).  A second hot spot was found in the SCR II domain around Y97, which282
resides in the lower half of the SCR II domain.  Like Ad35 (Fleischli et al., 2005) Ad3,283
7, 11 bound 40 –60% less efficiently to the Y97A mutant than to the wild type.  An284
additional binding reduction of all three Ads was found with the K110A and K119A285
mutations.  Both of these residues are located on the same SCR II face containing286
the antibody M177 epitope R69 and D70.287
288
DISCUSSION289
Receptor binding can be a major determinant of viral tropism, and the290
characterization of receptor binding mechanisms is of fundamental importance for the291
11
development of vectors for targeted gene transfer.  Here we supply evidence that292
both species B1 and B2 utilize CD46 as an attachment receptor for entry into cells,293
and document how the B1 species interact with CD46.294
The role of CD46 as an attachment receptor for all species B serotypes has been295
controversial.  Martilla et al. interpreted their data as indicating that CD46 represents296
a functional receptor for all species B viruses, but not for Ad3 and Ad7 (Marttila et al.,297
2005).  These authors suggested that Ad3 and Ad7 bind to an elusive common298
species B virus receptor (Gustafsson et al., 2006, Marttila et al., 2005, Segerman et299
al., 2003a, Segerman et al., 2003b).  These conclusions were mainly based on300
immunostainings of infected human A549 cells preincubated with a polyclonal anti-301
CD46 antibody or CHO cells expressing the BC1 isoform of CD46.  The dynamic302
range of the infectious readout and the anti-CD46 antibody blocking effect was not303
defined, and CHO cells expressing only few CD46 mutants were tested.  In studies304
by Gaggar et al. (Gaggar et al., 2003) and Tuve at al. (Tuve et al., 2006) all tested305
species B Ads except Ad3 and Ad7 were found to bind to CHO cells expressing the306
C2 isoform of CD46.  In contrast, we measure Ad3 and Ad7 binding and transgene307
expression in different rodent cells, including BHK, CHO, L929 and B16 cells.  These308
cells stably express all four major splice forms of human CD46, (this study,309
unpublished data and (Fleischli et al., 2005, Sirena et al., 2004)).  We assessed the310
efficiency of cell entry and gene delivery by eGFP expression in flow cytometry,311
which has a higher dynamic range than immunostaining experiments.  The312
discrepancy with respect to the findings of Tuve et al., and Gaggar et al. may be313
attributed to higher CD46 expression levels in our transfected rodent cells compared314
to the other studies.  We measured an 8-fold increase of Ad35 binding, compared to315
a 2-fold increase reported by Tuve et al. (Tuve et al., 2006).  We do not exclude the316
possibility that additional receptor(s) for species B serotypes exist, particularly, since317
antibody blocking experiments in human cells revealed only partial Ad3, Ad7, Ad11,318
Ad14 and Ad16 inhibition (Marttila et al., 2005, Segerman et al., 2003b, Sirena et al.,319
2004, Tuve et al., 2006), unlike in CD46-expressing rodent cells.  The analysis of320
species B serotype interactions with rodent cells expressing high CD46 levels321
reduces the complexity of virus receptor interactions.  Based on CD46 antibody322
12
blocking studies in K562 (Sirena et al., 2004) or HeLa cells (Tuve et al., 2006) which323
revealed a maximum 40% blocking of Ad3 binding, we suggest that the Ad-CD46324
interactions may reflect about 40% of Ad3 binding to human cells.  In contrast, B2325
serotypes may predominantely use CD46 as receptor (Tuve et al., 2006).326
Our results clearly demonstrate that the species B Ads 3, 7, and 11 engage CD46327
through similar binding surfaces as previously described for Ad35 (Fleischli et al.,328
2005, Gaggar et al., 2005, Sakurai et al., 2006).  This is based on antibody329
competition, soluble CD46 competition, binding assays to cells expressing truncated330
CD46 molecules, and single amino acid mutants of CD46.  The proposed glycan-free331
surface formed by the two flexibly linked CD46 SCR I-II domains (Fig. 5A) overlaps332
well with the binding surface of the recently resolved fibre knob Ad11-SCR I-II 3D333
structure with three contact areas A, B and C (Fig. 5B) (Persson et al., 2007).  Area334
A, with major contact-forming CD46 residues R25, 35FYI37 and 41ATHT44, overlaps335
with the epitope of the strongly virus inhibiting 13/42 antibody which includes336
residues D27, K31 and H43 and the P39-T44 loop (Buchholz et al., 1997).  The337
epitope of the second strongly blocking MEM-258 is contained in SCR I, but has not338
been mapped at the amino acid level (Fleischli et al., 2005, Sakurai et al., 2006).339
Strongly inhibiting antibodies may directly compete for the virus-binding site340
(Buchholz et al., 1997).  Area A binding explains also our results with single point341
mutants of CD46, where changes in K29, localized aside of residues 35FYI37, resulted342
in weak, but consistent reduction of binding for all four viruses.  In line with these343
results, we found reduced binding of some, but not all, species B viruses for residues344
K15, E24, R25, P39, L40 and loop mutation P39-T44.  These patterns of Ad binding345
to the mutagenised CD46 receptor nicely corroborated our antibody mapping results.346
The epitopes of the moderately binding-inhibiting SCR I antibodies are located in the347
upper third of the SCR I structure, adjacent to the epitope of 13/42 or binding area A.348
They include the E4.3 antibody, which binds to an epitope containing the critical E3349
residue (Fig. 5A, not visible as on opposite site).  At the highest concentration used,350
E4.3 blocked Ad3 and Ad7 by 52% and 61% respectively, whereas a weak inhibition351
of 16% for Ad35, and no significant inhibition of Ad11 were documented.  MCI20.6, a352
second antibody recognizing a different epitope on the SCR I tip with the critical R48353
13
residue had no effect on Ad3 and Ad7, and a very weak effect on Ad11 and Ad35354
binding with 14% and 17% blocking, respectively.  Tra-2, a third antibody interacting355
with SCR I through K17 on the upper third of SCR I reduced binding by 34, 35, 19356
and 21% to Ad3, Ad7, Ad11 and Ad35, respectively.  As weakly and moderately357
inhibiting monoclonal antibodies may exert their effects indirectly, hindering the virus358
receptor by steric long-range effects, rather than directly overlapping with the virus-359
binding site (Buchholz et al., 1997), it was anticipated that these epitopes do not360
colocalise with the virus binding sites.361
Due to lack of antibodies recognizing epitopes in binding area B, as well as a lack of362
single point mutants for this area containing 62RETC65 as major contact residues, this363
SCR I-II interface site could not be further defined here.  Area C with major contact-364
forming residues 68IRDPL72 (Persson et al., 2007) is confirmed by an overlap with the365
binding site of M177, which maps to the residues R69, D70 and E103 of the lower366
part of SCR II (Buchholz et al., 1997).  The two single point mutants K110A and367
K119A with less strong but consistent binding reduction are located near R69.  The368
same holds true for the single point mutant Y97A which revealed the highest impact369
on virus binding for all four serotypes.  Of note, residue Y97 is part of the six amino370
acid exchange mutant 96 to 101 (adapted numbering), and residue K119 is part of371
the five amino acid exchange mutant 118 to 122, both causing complete loss of372
Ad35-mediated transgene expression (Gaggar et al., 2005).  Since Y97 is located at373
the lower end of the SCR II module, it may be involved in interdomain contacts and374
exert an indirect effect on virus binding (Liszewski et al., 2000).  This is particularly375
interesting, as SCR III-IV domains are positioned at an angle of about 90° relative to376
SCR I-II (Persson et al., 2007).  In the absence of SCR III-IV structural data, the377
variable effects of the GB24 antibody recognizing epitopes in SCRIII-IV (Liszewski et378
al., 2000) on different Ad serotypes is difficult to interpret.  Differences in blocking379
efficiencies of the moderately and weakly blocking antibodies could hint towards the380
exact binding area.  That the binding interface can vary to some extent among the381
different Ad serotypes has been documented for the CAR-binding serotypes (for382
review see (Law & Davidson, 2005).  An additional interesting finding is that the Ad3 /383
Ad7 pair and Ad11 / Ad35 pair have similar binding patterns.  This could relate to384
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differences in the fibre sequences, particularly the two unique hydrophobic residues385
240 and 296 shared only by Ad3 and Ad7 (Chroboczek et al., 1995, Marttila et al.,386
2005).387
Whether such minor binding differences can explain the difference in blocking activity388
of soluble CD46ex-Fc for Ad3 and Ad7 is unclear and remains to be investigated.389
The dimer structure of CD46ex-Fc may not be responsible for this difference, since390
soluble extracellular CD46 proteins devoid of the Fc showed identical behaviour (data391
not shown).  It is perhaps more likely that Ad3 and Ad7 bind to an oligomeric form of392
CD46 that is different from the oligomer bound by Ad11 and Ad35.  Alternatively, an393
unknown factor could hetero-oligomerise with CD46 and hence modulate the394
affinities of CD46 to Ad3 and Ad7, or Ad11 and Ad35.  This differential effect of395
CD46ex also implies that levels of CD46 are crucial for distinguishing binding of B1396
and B2 serotypes.397
398
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Legends to figures551
Fig. 1. CD46-dependent binding and transgene expression of species B552
adenoviruses.  (A) 5 x 105 of human A549 cells, rodent BHK, and CD46-or CAR-553
transfected BHK cells were incubated on ice with 1000 vp of the indicated [3H]-554
labelled species B serotypes.  After incubation for 2 h, the cells were washed and555
cell-associated radioactivity was determined.  Mean values and standard deviations556
of triplicates from one representative experiment are shown.  (B) For expression557
analyses, cells were incubated with eGFP expressing Ad3, Ad7, Ad11, Ad35 and Ad5558
vectors at increasing MOIs of 1, 10, 100 vp/cell for A549, and 1, 10, 100, and 1000559
vp/cell for BHK cells.  eGFP expression was analysed two days p.i. by flow560
cytometry.  Results are expressed as means of fluorescence intensity (MFI).561
Fig. 2.  Inhibition of Ad3, Ad7 and Ad11 binding to CD46 by anti-CD46 antibodies562
and soluble CD46ex-Fc.  (A) Ad binding inhibition by CD46-specific antibodies.  BHK-563
CD46 cells were incubated with the indicated CD46-specific antibodies, control564
antibody E1-1 anti-CAR, or a 30-fold excess of cold Ad, followed by the addition of565
[3H]-Ad at 4°C.  Virus binding was measured by liquid scintillation counting.  The data566
were normalized to the amounts of virus bound in the absence of inhibitors and are567
represented as average of triplicate determinations including standard deviations.568
The asterisks indicate the level of significance (P values of <0.05 [single asterisk] and569
<0.005 [double asterisk] for comparison with E1-1 control).  (B) Summary of binding570
inhibition data with monoclonal antibodies.  Percentage of residual binding is571
depicted as follows: >90% (), 76-90% (), 51-75% (), 25-50%572
(), <25% ().  Amino acid residues mainly involved in antibody binding573
sites and their positions are indicated.  For further details refer to Fig. 5 and574
(Buchholz et al., 1997).  ataken from (Fleischli et al., 2005).  (C) Ad3, Ad7 and Ad11575
binding inhibition by soluble CD46ex-Fc.  BHK-CD46 cells were incubated with the576
indicated amounts of CD46ex-Fc or control CARex-Fc, followed by the addition of577
[3H]-Ads.  The subsequent processing was as described in (A).578
Fig. 3.  Ad3, Ad7, and Ad11 binding efficiencies and transgene expression mediated579
by CD46-CD4 hybrid proteins.  Proteins were transiently expressed in Ltk- cells (for580
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binding assays) and BHK cells (for transgene expression) using the VV-T7 system.581
CD46 surface expression levels of the various CD46-CD4 hybrid constructs were582
normalized to the surface expression levels of CD46-BC1.  Binding efficiencies were583
calculated by dividing the [3H]-Ad binding values by surface expression levels and are584
shown in relation to that of the CD46-BC1 standard.  Likewise, luciferase transgene585
expression measured by infection of the CD46 expressing cells with Ad3CMV-luc and586
Ad11CMV-luc 24 h post transduction was determined by normalizing to protein587
concentration and surface expression of the CD46 proteins, attributing 100% to the588
BHK cells expressing CD46 (BC1).  Measurements were done in triplicates and589
repeated at least three times.  CD46 expression levels are indicated for Ltk- cells590
only, but were similar for BHK cells.  Schematics indicate the following: SCR I (black),591
SCR II (crosshatched), SCR III (light grey), and SCR IV (white).  The CD4 Ig-like592
domain is drawn as a loop.  N-linked oligosaccharides of SCR domains are indicated,593
whereas the single oligosaccharide of the CD4 Ig-like domain is omitted.  (A, C, E)594
Function of four hybrid proteins containing SCR I-IV fused to increasing numbers of595
CD4 Ig-like domains.  (B, D, F) Function of six hybrid proteins containing SCR I-II596
fused to increasing numbers of CD4 Ig-like domains, or combined with mutations597
ablating N-linked oligosaccharide in SCR I (dg1) or SCR II (dg2).  Note that598
transgene expression with Ad7 was not included and that CD46 surface expression599
levels are only once depicted in A and B, and identical in C, D, E, and F.600
Fig. 4.  Ad3, 7 and 11 binding efficiencies mediated by 36 single amino acid SCR I-II601
mutant proteins.  (A) 19 single amino acid mutants plus the exchange mutant P39-602
T44 containing six alanines replacing the endogenous sequence localized in SCR I603
were analyzed as in Fig. 3.  (B) 17 single amino acid mutants of SCR II were similarly604
analyzed.605
Fig. 5.  Localization of species B Ad binding to CD46 SCR I-II structure.  (A) Space-606
filling drawing of the CD46 SCRI-II structure (Casasnovas et al., 1999) were prepared607
with the program MOLMOL (Koradi et al., 1996) using the Brookhaven protein data608
bank (code 1ckl).  Light blue: SCR I; dark blue: SCR II; green: N-glycans; pink:609
residues involved in antibody binding of 13/42 (D27, K31, H43), MCI20.6 (R48), Tra-2610
(K17, all SCR I) and M177 (R69, D70, SCR II) (Buchholz et al., 1997); yellow:611
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reduction of binding in single point mutants.  (B) Identical to (A), with superimposed612
binding residues (in red) deduced from fibre knob Ad11-SCR I-II 3D structure613
(Persson et al., 2007).614
615
616






1Supplementary data1
Construction Ad3CMV-eGFP, Ad3CMV-luciferase and Ad7CMV-eGFP.  For the2
construction of Ad3 and Ad7 vectors containing the eGFP or luciferase expression3
cassette in the forward orientation in the deleted E1 region we used a recently4
developed recombineering protocol (Warming e t  a l . ,  2005)5
(http://recombineering.ncifcrf.gov/).  For the construction of the Ad3CMV-eGFP6
vector, the bacterial artificial chromosome (BAC) plasmid pKSB2Ad3wt (Sirena et al.,7
2005) served as starting vector to insert a forward-oriented eGFP expression8
cassette.  For this, the galK expression cassette was PCR-amplified using the9
f o r w a r d  p r i m e r  5 ’ -10
TGCCAGCGAGAAGAGTTTTCTCCTCCGCGCCGCAAGTCAGCCTGTTGACAATTA11
A T C A T C G G C A  a n d  t h e  r e v e r s e  p r i m e r  3 ’ -12
TTAAGCTCACTCTGGAAAAGGCATCTGGTTCCAACATTACTCAGCACTGTCCTGC13
TCCTT.  Replacement of the targeted Ad3 sequence and selection on galactose14
minimal medium was performed in E. coli SW102.  The CMV-eGFP cassette was15
P C R - a m p l i f i e d  u s i n g  t h e  f o r w a r d  p r i m e r  5 ’ -16
TGCCAGCGAGAAGAGTTTTCTCCTCCGCGCCGCAAGTCAGCCATTGCATACGTT17
GTATCC in  comb ina t ion  w i th  the  reve rse  p r imer  3 ’ -18
TTAAGCTCACTCTGGAAAAGGCATCTGGTTCCAACATTACTTCTTTCCCACCCTT19
AAGCC.  The sequence of the forward primer was identical to Ad3 sequence 521 to20
560, whereas the second primer was identical to sequence 3141 to 3180, resulting in21
a 2580-bp deletion of the E1 region encompassing the sequence from nucleotide 56122
to 3140.  This deletion comprised the ORFs for E1A and most of E1B, but left intact a23
residual 298-bp stretch of the pIX promoter.  Release of the viral genome by the24
flanking unique Mlu I endonuclease sites was followed by transfection of helper 911-25
Ad3E1B cells, harbouring the open reading frame of Ad3 E1B under control of the26
mouse phospho-glycerate kinase promoter (Sirena et al., 2005).  For large batch27
preparation, the virus was amplified in 293-2V6.11 cells, harbouring a Ponasterone-28
inducible E4orf6 (Brough et al., 1996).  Ad3CMV-Luc was similarly constructed using29
the same primers as above for eGFP expression cassette for the luciferase30
expression cassette (Havenga et al., 2001).31
2For the Ad7CMV-eGFP construction, left and right terminal Ad7 sequences,32
separated by a zeocin selection cassette, were first cloned into pBluescript, followed33
by subcloning of the Ad7LRzeo-cassette into pKSB2 (Sirena et al., 2005).  For this, a34
477-bp of the Ad7 left end sequence was PCR-amplified using the forward primer 5’-35
GCTCTAGAGTTTAAACTATCTATATAATATACCTTATAG-3’ (inserting the restriction36
si tes X b a  I and P m e I ) ,  and the reverse pr imer  5 ’ -37
GATCGAATTCGGTACCACTAGTATTTAAATTAGCGATCAGCTGACACC-3’38
(inserting the restriction sites Spe I, Kpn I, EcoRI).  The second fragment39
encompassing 704-bp of the right Ad7 end sequence was amplified using the forward40
primer 5’-GGAATTCCCTAGGCAGGGTCTCCAGCTCGACCC-3’ (inserting the41
restr ict ion si tes E c o RI, A v r  II) and the reverse primer 5’-42
GCCCAAGCTTGGATCCGTTTAAACTATCTATATAATATACCTTATAG-3’) (inserting43
the restriction sites Pme I, BamHI, Hind III).  PCR fragments were cloned sequentially44
into pBluescript® starting with the left fragment (Xba I, EcoRI) followed by the right45
fragment (EcoRI and Hind III).  For further selection purposes, the resistance gene46
Sh ble (Zeocin™resistance) was PCR-amplified from pcDNA3.1 zeo (Invitrogen) and47
cloned into the Spe I site, located in-between the Ad7 fragments.  In order to48
generate pKSB2Ad7LRzeo, the Ad7LRzeo-cassette was cloned into Not I-BamHI-49
restricted pKSB2.  Subsequently, E. coli SW102 were co-transformed with Avr II-50
linearised pKSB2Ad7LRzeo and genomic Ad7 DNA to generate pKSB2Ad7.  Deletion51
of the E1A region and insertion of the CMV-eGFP cassette was accomplished as52
described above for Ad3CMV-eGFP, using the same primers sets.  In Ad7, this led to53
a 2579-bp deletion from 561 to 3141.  Release of the viral genome by the flanking54
unique Pme I endonuclease sites and subsequent virus production was performed as55
described above.56
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